Compare Davita Inc (DVA) vs Xpeng Inc - ADR (XPEV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Xpeng Inc - ADR — how do they compare? Davita Inc trades at $178.5 (market cap $11.38B), while Xpeng Inc - ADR trades at $11.73 (market cap $11.15B). The key difference: Davita Inc and Xpeng Inc - ADR are close in size by market cap, and Davita Inc is trading nearer its 52-week high, Xpeng Inc - ADR nearer its low. Which is the better fit depends on your goals.
| DVA | XPEV | |
|---|---|---|
Market Cap | $11.38B | $11.15B |
Sector | Health | Consumer Cyclical |
52-Week High | $240.96 | $28.07 |
52-Week Low | $103.87 | $11.68 |
Enterprise Value | $24.10B | $13.28B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XPeng (XPEV) trades at $12.00, down 1.07% on the day, with a bearish technical signal. The company reported Q1 2026 revenue of $76.72 billion but a net loss of $1.14 billion, though the net margin improved to -1.49% from -14.17% in 2024. Recent news highlights vehicle delivery growth, international expansion, and advancements in autonomous driving technology.
The outlook is mixed: strong revenue growth and analyst buy ratings (64.7% consensus) suggest upside to the $17.00 price target, but persistent losses, high EV/EBITDA of 40.09, and competitive pressures pose risks. Investor sentiment is cautious amid earnings volatility and macroeconomic headwinds in the EV sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Xpeng Inc - ADR
Founded in 2015, XPeng is a leading Chinese smart electric vehicle, or EV, company that designs, develops, manufactures and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold over 98,000 EVs in 2021, accounting for about 3% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.
Read more on XPEV →
